Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes.

[1]  A. Siddiqui,et al.  Hepatitis C virus hijacks host lipid metabolism , 2010, Trends in Endocrinology & Metabolism.

[2]  Y. Hirata,et al.  Hepatitis C Virus Impairs p53 via Persistent Overexpression of 3β-Hydroxysterol Δ24-Reductase* , 2009, The Journal of Biological Chemistry.

[3]  R. Cenedella.  Cholesterol Synthesis Inhibitor U18666A and the Role of Sterol Metabolism and Trafficking in Numerous Pathophysiological Processes , 2009, Lipids.

[4]  A. Lonardo,et al.  Statins in liver disease: A molehill, an iceberg, or neither? , 2008, Hepatology.

[5]  C. Aston,et al.  Fluvastatin Inhibits Hepatitis C Replication in Humans , 2008, The American Journal of Gastroenterology.

[6]  Y. Hirata,et al.  Serine Palmitoyltransferase Inhibitor Suppresses HCV Replication in a Mouse Model , 2008 .

[7]  Y. Inoue,et al.  Critical Role of Virion-Associated Cholesterol and Sphingolipid in Hepatitis C Virus Infection , 2008, Journal of Virology.

[8]  M. Kohara,et al.  Evaluation of a cyclophilin inhibitor in hepatitis C virus–infected chimeric mice in vivo , 2007, Hepatology.

[9]  S. Kuge,et al.  Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. , 2007, Biochemical and biophysical research communications.

[10]  M. Honda,et al.  Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C , 2006, Hepatology.

[11]  K. Naka,et al.  Different anti‐HCV profiles of statins and their potential for combination therapy with interferon , 2006, Hepatology.

[12]  M. Kohara,et al.  Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype , 2006, Gene Therapy.

[13]  R. Nitsch,et al.  The role of seladin‐1/DHCR24 in cholesterol biosynthesis, APP processing and Aβ generation in vivo , 2006, The EMBO journal.

[14]  M. Aoki,et al.  Host sphingolipid biosynthesis as a target for hepatitis C virus therapy , 2005, Nature chemical biology.

[15]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[16]  M. Pierotti,et al.  DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress‐induced apoptosis , 2005, International journal of cancer.

[17]  F. Chisari,et al.  Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Chaowei Wu,et al.  Regulation of cellular response to oncogenic and oxidative stress by Seladin-1 , 2004, Nature.

[19]  T. Asahara,et al.  Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.

[20]  M. Oulad-Abdelghani,et al.  Molecular Characterization of the Microsomal Tamoxifen Binding Site* , 2004, Journal of Biological Chemistry.

[21]  M. Lai,et al.  Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. , 2004, Virology.

[22]  Yutaka Hoshikawa,et al.  Activation of the CKI-CDK-Rb-E2F Pathway in Full Genome Hepatitis C Virus-expressing Cells* , 2004, Journal of Biological Chemistry.

[23]  P. Einat,et al.  Generation of Viable Cholesterol-Free Mice , 2003, Science.

[24]  M. Gale,et al.  Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Burroughs,et al.  Hepatocellular carcinoma , 2003, The Lancet.

[26]  L. Wodicka,et al.  Genomic analysis of the host response to hepatitis C virus infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Hans R. Waterham,et al.  Mutations in the 3β-Hydroxysterol Δ24-Reductase Gene Cause Desmosterolosis, an Autosomal Recessive Disorder of Cholesterol Biosynthesis , 2001 .

[28]  D. Tyrrell,et al.  Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.

[29]  R. Nitsch,et al.  The Human DIMINUTO/DWARF1 Homolog Seladin-1 Confers Resistance to Alzheimer's Disease-Associated Neurodegeneration and Oxidative Stress , 2000, The Journal of Neuroscience.

[30]  R. Kawaguchi,et al.  Real-time detection system for quantification of hepatitis C virus genome. , 1999, Gastroenterology.

[31]  W. Bowen,et al.  99mTc-labeled sigma-receptor-binding complex: synthesis, characterization, and specific binding to human ductal breast carcinoma (T47D) cells. , 1997, Bioconjugate chemistry.

[32]  M. Kohara,et al.  Hepatitis C Virus Genotypes 1 and 2 Respond to Interferon-a with Different , 1995 .

[33]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[34]  T. Yamane,et al.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. , 1982, Cancer research.

[35]  C C Howe,et al.  Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. , 1980, Science.

[36]  R. Cenedella,et al.  Induction of chronic epileptiform activity in the rat by an inhibitor of cholesterol synthesis, U18666A , 1978, Brain Research.

[37]  P. Vreken,et al.  Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. , 2001, American journal of human genetics.

[38]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[39]  A. Shevchenko,et al.  Sample preparation methods for mass spectrometric peptide mapping directly from 2-DE gels. , 1999, Methods in molecular biology.

[40]  M. Kohara,et al.  Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics. , 1995, The Journal of infectious diseases.